Regulatory Approvals

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

By

Regulatory Approvals — FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors  Oncodaily

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 3, 2026.

By

Related Post

Regulatory Approvals

FDA approves 1st-of-its-kind pill to reduce cholesterol

Regulatory Approvals

FDA approves Ponlimsi, a biosimilar for preventing fractures in prostate and breast cancer patients

Regulatory Approvals

AbbVie Just Won FDA Approval for a Once-Daily Parkinson’s Pill. Here’s Why It Matters More Than You Think.

Financial News For All

Litigation

FTC, Washington win $225M Amway settlement over alleged deceptive recruiting tactics

Litigation

‘Tomato fraud’: Cento accused of using the San Marzano namesake in its products in new lawsuit company calls meritless

Mergers & Acquisitions

Casey Bloys: Post-Merger Could See Paramount+, HBO Max Bundle

Mergers & Acquisitions

South Dakota Supreme Court to consider western judicial circuit merger